P atients with increased levels of parathyroid hormone (PTH), resulting from primary hyperparathyroidism or chronic kidney disease (CKD) with secondary hyperparathyroidism, have high risk for cardiovascular diseases (CVDs) and death. 1, 2 
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results from the whole-body MRI angiography are achieved in one single session and are in agreement with the established gold standard method based on conventional angiography and are associated with cardiovascular outcomes. 16, 17 As a second step, we studied the prospective association between PTH and the risk of peripheral and large vessel atherosclerotic disease in an independent community-based sample of elderly men.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results

Baseline Characteristics
Baseline characteristics of both cohorts are shown in Tables 1  and 2 . Individuals in ULSAM and PIVUS had similar age (70 and 71) and body mass index (26.3 and 27) , with a smoking prevalence of 20% in the former and 9% the latter.
PTH Levels and Vascular Disease
PIVUS
Higher levels of PTH were associated with increasing atherosclerotic burden according to whole-body magnetic resonance angiography (WBMRA) in linear regressions (Model D: 1 SD increase in PTH was associated with 0.041 higher category of total atherosclerosis score, 95% confidence intervals [CI; 0.002-0.08], P=0.038). This association was present in all models, adjusting for vascular risk factors and for mineral metabolism ( Table 3 ). The relation between PTH and total atherosclerosis score showed no deviation from linearity when introducing a quadratic term of PTH (P=0.84) or at visually inspection.
ULSAM
Cox-Regression Models
During follow-up (ULSAM, median 16.7 years, range 0.01-20.4 years), 89 individuals were diagnosed with nonfatal atherosclerotic disease (incidence rate 5.46 [4.43-6 .72] per 1000 personyears at risk [PYAR]), and 152 participants were diagnosed with the composite end point of both nonfatal and fatal atherosclerotic disease (incidence rate 9.28 [7.91-10.9] per 1000 PYAR).
In Cox proportional hazards analyses, 1 SD increase of PTH was associated with a 38% to 55% higher risk for nonfatal atherosclerotic disease in all models (Models A-D, Table 4 ). Men in the highest quartile of PTH had up to a 2-fold higher risk of developing atherosclerotic disease compared with those in the first quartile and more than one and a half fold higher risk for atherosclerotic disease compared with participants in quartiles 1 to 3 in models A-D (Table 3, Figure 1 ). The associations between PTH and vascular disease in model D were similar when using propensity score adjustment (HR for quartile 4 versus quartiles 1-3: 1.73, 95% CI [1.06-2.83]; P=0.03). The relation between PTH and atherosclerotic disease showed no deviation from linearity when introducing a quadratic term of PTH (P=0.47), and a regression spline graph also suggests that there seems to be a linear increase in hazard for atherosclerosis (Figures 2 and 3 ) and the combination of disease and death because of atherosclerosis, with increasing PTH levels. In secondary analyses, a 1 SD increase in plasma-PTH was associated with a 32% to 46% higher risk for fatal and nonfatal atherosclerotic disease (Models A-D, Table 5 ).
Population-Attributable Risk Proportion
Elevated PTH (as defined by the quartile 4 versus 1-3 cutoff, plasma-PTH>5.27 pmol/L) accounted for 11.6% (95% CI [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] ) of the population-attributable risk proportion (PAR) for nonfatal atherosclerotic disease. The PAR values for the other cardiovascular risk factors in model D are given in Table 6 (corresponding Cox proportional hazard ratios for vascular risk-factors are presented in Table I in the online-only Data Supplement). PTH and smoking were the only variables associated with vascular atherosclerotic disease.
Sensitivity Analysis
Furthermore, in model D, in individuals without CKD (1 SD increase of PTH: HR, 1.55; 95% CI [1.10-2.19]; P=0.012) or hypercalcemia (HR for 1 SD increase of PTH: 1.52; 95% CI [1.25-1.85]; P<0.0001), respectively, the associations between PTH and vascular disease were similar in all models, as well as when adding C-reactive protein, cystatin C, N-terminal proB-type natriuretic peptide, and troponin I to the model D for the whole cohort (1 SD increase of PTH; HR, 1.51; 95% CI [1.24-1.85]; P<0.0001). 
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Discussion
Principal Findings
In the present study, increasing levels of the hormone PTH, a key regulator of the mineral metabolism, were associated with the level of atherosclerotic burden as assessed by WBMRA in a community-based cohort of the elderly. Moreover, adding further support and additional clinical relevance of these findings, higher PTH was associated with an increased risk for clinically overt nonfatal atherosclerotic disease, independently of both established risk factors for CVDs and of mineral metabolism in an independent community-based cohort of elderly men. Elevated plasma levels of PTH accounted for ≈12% of the population-attributable risk proportion for clinical atherosclerotic disease, on par in risk with smoking. These finding indicate that elevated PTH could have substantial public health implications.
Comparison With Previous Studies
The present results are in accordance with previous experimental and clinical studies reporting vascular abnormalities with increasing levels of PTH, 18, 19 but no previous study has presented data on PTH in relation to atherosclerosis in different arterial territories as assessed by whole-body angiography. Furthermore, the findings that PTH concentrations predict vascular diseases and death have been thoroughly described in studies of patients with mineral metabolism diseases such as primary and secondary hyperparathyroidism as well as CKD. 1, 2, 4, 5, [20] [21] [22] Also in the community-based setting, higher PTH have been shown to be associated with an increased risk for cardiovascular mortality, a composite end point predominantly consisting of death attributable to coronary heart disease and cerebrovascular disease, 7 or the risk for heart failure. 8, 23 The association between PTH and the risk for peripheral or large vessel atherosclerotic disease has not been reported previously in the community-based setting.
Potential Mechanisms
Several mechanisms may explain the relationship between PTH and atherosclerotic disease in this study. First, PTH has been related to atherogenesis via vascular calcification and vascular remodeling both via direct PTH receptor interaction on the vessel as well as indirectly via inflammation and vascular dysfunction. 5, 6, 18, 19 Second, PTH seems to be involved in diseases of the myocardium via induction of left ventricular hypertrophy, congestive heart failure, cardiac calcification and fibrosis, detrimental states that all have secondary negative effects on the vasculature. 8, [24] [25] [26] [27] Third, higher PTH is associated with both established cardiovascular risk factors 28, 29 and more recently described risk factors such as markers of inflammation, renal dysfunction, and cardiac pathology. 8, 30, 31 The fact that PTH was consistently associated with atherosclerotic disease and death in all multivariable models suggests that confounding by these other factors is not the sole explanation for our findings. Moreover, the results from the WBMRA provide further support of previous data of PTH being associated to subclinical and clinical atherosclerotic diseases.
In this study setting, it is not possible to fully investigate the separate contribution by PTH on the development of Values are means (±SD), median (interquartile ranges), and n (%) for categorical variables. Conversion factor for plasma-parathyroid hormone (P-PTH; from pmol/L to pg/mL): [(pmol/L)/0.1053]. PIVUS indicates Prospective investigation of the vasculature in Uppsala seniors; and ULSAM, Uppsala longitudinal study of adult men. atherosclerosis in relation to other mineral metabolism variables because the levels are highly dependent on each other. Furthermore, all variables in the mineral metabolism have been associated with the development of CVDs, ranging from subclinical endothelial dysfunction to myocardial infarction and cardiovascular death. 11, 12, 23 However, in this study, the association between PTH and atherosclerosis persisted after adjustments for vitamin D status (serum 25-hydroxyvitamin D levels determined by the gold standard method), time of year for biochemical analysis, and other mineral metabolism variables, in conjunction with persistent results associating PTH and atherosclerotic in an independent cohort with another modality assessing degree of atherosclerosis.
Table 3. PIVUS. Multiple Linear Regression Analysis of Plasma-PTH to Total Atherosclerotic Burden (n=306) Analyzed With Whole-Body Magnetic Resonance Angiography
Clinical Implications
Because vascular diseases in the community are common and often have negative impact on the individual as well as being a burden for society, there is a great need to explore underlying mechanisms. 32, 33 As different cardiovascular risk factors have different impact on the prediction of atherosclerotic disease in different parts of the vasculature, it was important to also investigate the association between PTH and atherosclerosis outside the heart and brain. In patients who are treated or cured from disorders of mineral metabolism, cardiovascular abnormalities, such as hypertension, vascular dementia, and vascular calcifications, may improve or not progress further. [34] [35] [36] If future studies could show that PTH lowering leads to a reduced atherosclerotic burden, there is potentially a large public health implication because PTH lowering could fairly be managed by vitamin D fortification of the diet or by supplementation. Although PTH was associated to atherosclerotic events and to imaging evidence of atherosclerosis in the present study, the use of measuring PTH in a clinical setting for risk assessment remains to be evaluated. 
Strengths and Limitations
Strengths include the use of 2 large, homogenous, communitybased populations, with detailed characterization of potential confounders, and in ULSAM a long follow-up. Furthermore, the association between PTH and atherosclerosis was strengthened by WBMRA associating PTH and manifest atherosclerosis. Limitations in the PIVUS study include that MR investigations were only performed in a random subset of the individuals. The total atherosclerotic burden is partly based on a visual assessment and manual measurement of degree of vascular pathology that may introduce error. However, the relation between atherosclerosis detected on WBMRA and vascular outcomes has been described previously, 16 and results from WBMRA investigations are in agreement with digital subtraction angiography, the gold standard method for assessing degree of atherosclerotic burden. [37] [38] [39] Also, the manual assessment was blinded to measures of PTH. Increased support for the validity of our findings are previous studies strongly relating imaging evidence of burden of atherosclerosis to increased risk of disease and death from atherosclerotic diseases. 15, 16 Limitations in the ULSAM study include the unknown generalizability to women and for both cohorts, to other age-and ethnic groups because we only examined individuals of the same age and ethnic background.
Because of the large number of covariates in the fully adjusted model and risk of overfitting, we applied a propensity score to the model to decrease the risk of introducing random errors.
In both cohorts, levels of plasma-PTH and other variables included in the models were measured only at the baseline examination, and it is not known how well a single measurement reflects the PTH levels during the follow-up. Yet, any potential bias by variations in PTH levels over time would most likely conservatively bias our risk estimates because PTH increases with ageing. Albeit this uncertainty, the data clearly show that a spot sample of plasma-PTH levels is an independent predictor for both clinical and subclinical atherosclerotic disease. Further studies are needed to properly address the issue of identifying clinically relevant thresholds of circulating PTH for risk prediction purposes.
Conclusions
Increasing levels of PTH was associated with degree of atherosclerotic burden assessed by WBMRA and predicted morbidity and mortality of peripheral and large vessel atherosclerotic disease, in 2 independent cohorts in the community. Our data add to the notion that PTH may play an important role for the development of atherosclerosis in both peripheral and central arteries. 
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